• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  
Loading Events

« All Events

  • This event has passed.

14th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders

March 26, 2019 - March 31, 2019

  • « AETIONOMY final symposium and IMI neurodegeneration initiatives
  • 11th annual Adaptive Designs in Clinical Trials conference »

The 14th​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2019), will be held on 26-31 March in Lisbon, Portugal.

Jose Luis Molineuvo from BBRC will be presenting EPAD and its sister project AMYPAD at an AD/PD preconference meeting entitled “The Promise and Pitfalls of Real-world evidence in Alzheimer’s Disease”. This pre-conference full day satellite symposium will be held on Tuesday, March 26 (08:30 -17:00). Pre-Registration is required. To register, please click here.

+ Google Calendar+ iCal Export

Details

Start:
March 26, 2019
End:
March 31, 2019
Website:
https://adpd.kenes.com/2019#.XEW19ExFzcs

Venue

Centro de Congressos de Lisboa Lisboa Congress Centre Praça das Indústrias 1300-307, Lisboa, Portugal
  • « AETIONOMY final symposium and IMI neurodegeneration initiatives
  • 11th annual Adaptive Designs in Clinical Trials conference »
Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
    2021-04-06
  • AD Workbench
    The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
    2021-03-18
  • EPAD_WordCloud
    EPAD releases its first data and sample access bulletin
    2021-03-10
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

If you're attending #BNA2021, check out the pre-registration poster from @GregorySarah introducing the SPeAk study. Participants of this new study must have previously enrolled in the @IMI_EPAD LCS or CHARIOT Pro study at @CenDemPrevent. #biomarker #Alzheimer’s disease #dementia twitter.com/CenDemPrevent/…

reply retweet favorite
10:18 am · 2021-04-14
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the last @IMI_EPAD publication on the application of the #ATN classification scheme in the first 1500 participants consented in the EPAD Longitudinal Cohort Study. ep-ad.org/2021/04/06/new… @silvia_ingala @IMI_JU @EFPIA @EU_H2020 pic.twitter.com/3HhgMcBDN0

reply retweet favorite
8:15 am · 2021-04-13
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Bioresource consists of over 100,000 samples consisting of blood, CSF, saliva and urine that have been collected annually from research participants throughout their participation in the Longitudinal Cohort Study. #OpenAccess ep-ad.org/2021/03/10/epa… twitter.com/IMI_EPAD/statu… pic.twitter.com/dRjuI1opFi

reply retweet favorite
7:16 am · 2021-04-12
Twitter
EPAD
EPAD
@IMI_EPAD

The ATN classification has been added for public use to the analytical database of the @IMI_EPAD Longitudinal Cohort Study, hosted by @aridhia . ⬇️ ep-ad.org/2021/04/06/new… twitter.com/IMI_EPAD/statu…

reply retweet favorite
5:56 am · 2021-04-07
Twitter
EPAD
EPAD
@IMI_EPAD

In this article, the #ATN classification was operationalized in the first 1500 participants consented in the @IMI_EPAD cohort, a deeply phenotyped cohort of individuals who do not have #dementia. ep-ad.org/2021/04/06/new…

reply retweet favorite
7:08 am · 2021-04-06
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.